Enveric Biosciences Secures 23rd U.S. Patent for Novel Neuroplastogenic Compounds Targeting Mental Health Disorders
Enveric Biosciences has secured its 23rd U.S. patent, U.S. Patent No. 12,428,408, for novel neuroplastogenic compounds aimed at treating mental health disorders. The patent covers a series of fused heterocyclic mescaline derivatives that target serotonin receptors and promote neuroplasticity. This achievement is part of the company's strategy to enhance its intellectual property portfolio and develop next-generation treatments for neuropsychiatric conditions.
Enveric Biosciences announced the issuance of its 23rd U.S. patent for novel compounds within its neuroplastogenic patent estate. The new patent, U.S. Patent No. 12,428,408, titled “Fused Heterocyclic Mescaline Derivatives,” covers a unique series of compounds designed to target key serotonin receptors and promote neuroplasticity. The company highlighted this milestone as part of its ongoing efforts to expand its intellectual property portfolio and advance next-generation molecules for potential treatment of neuropsychiatric conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251016672946) on October 16, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
